Open AccessExpression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma
Author(s) -
Ruolin Li,
Gang Chen,
YiWu Dang,
RongQuan He,
AnGui Liu,
Jie Ma,
Zhian Ling
Publication year - 2021
Publication title -
technology in cancer research and treatment
Language(s) - English
Resource type - Journals
eISSN - 1533-0346
pISSN - 1533-0338
DOI - 10.1177/15330338211024551
Subject(s) - downregulation and upregulation , multiple myeloma , immunohistochemistry , microarray , microarray analysis techniques , cancer research , bone marrow , gene , medicine , pathology , gene expression , biology , immunology , genetics
Multiple myeloma (MM) is one of the main blood disorders threatening human health today. This study aimed to examine the expression of BCL-2/adenovirus E1B 19 kDa-interacting protein 3-like (BNIP3L) in patients with MM and explore its mechanisms in silico. Bone marrow samples (n = 36 from patients with MM and n = 12 from healthy donors) were used to conduct BNIP3L expression analysis using immunohistochemistry. Microarray or RNA sequencing data from the Sequence Read Archive, Gene Expression Omnibus, and ArrayExpress databases were used to appraise BNIP3L expression and its prognostic role in patients with MM. The co-expressed genes of BNIP3L were identified for enrichment and protein-protein interaction (PPI) analyses to determine the associated signaling pathways. Immunohistochemistry indicated that BNIP3L expression in bone marrow of patients with MM was significantly lower than that in bone marrow of healthy donors. BNIP3L mRNA expression was also significantly lower in patients with MM than in healthy donors. The overall standard mean difference (SMD) for downregulation of BNIP3L was −0.62 [−1.17, −0.06], and the area under the curve was 0.81 [0.78, 0.85] based on a total of 694 MM cases. The overall survival analysis demonstrated that BNIP3L levels could act as an independent protective indicator of MM patient survival (HR = 0.79). Moreover, 261 co-expressed genes of BNIP3L were confirmed and found to be mainly involved in the adipocytokine signaling pathway. We preliminarily proved that downregulation of BNIP3L may play an important role in the occurrence and development of MM, and the promoting cancer capacity may be related to the pathway of adipocytokine signaling pathway.